Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082803 · ClinicalTrials.gov registry record · Phase 1
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
A Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Treeline Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 11
- Study locations
NCT07082803 is a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin that is actively recruiting participants, run by Treeline Biosciences. The registered enrollment target is 180 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (63% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT07082803, a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, is actively recruiting participants, sponsored by Treeline Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 11
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Conditions Studied
Interventions
- DRUG TLN-121
- DRUG TLN-254
Study Locations (11)
Victoria
- Cabrini Health - Malvern
- Peter MacCallum Cancer Centre - Melbourne
California
- Stanford Medicine Cancer Center - Palo Alto
Michigan
- The START Center for Cancer Care - Midwest - Grand Rapids
Missouri
- Washington University School of Medicine - St Louis
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
New South Wales
- Macquarie University Hospital - Macquarie Park
Queensland
- Princess Alexandra Hospital - Woolloongabba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2030-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07082803
The ClinicalTrials.gov registry entry for NCT07082803 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (63% lower). The listed sponsor is Treeline Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which TLN-121 is the first listed.
NCT07082803 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Victoria, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT07082803 about?
NCT07082803 is a clinical study titled "TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas". The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
What is the current status of trial NCT07082803?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2025-06-23. Estimated completion is 2030-11.
What conditions does trial NCT07082803 study?
This clinical trial studies the following conditions: Lymphoma, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT07082803?
The interventions under investigation include: TLN-121 (DRUG), TLN-254 (DRUG).
Who is sponsoring clinical trial NCT07082803?
This trial is sponsored by Treeline Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082803 being conducted?
This trial has 11 study locations across California, Michigan, Missouri, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.